Skip to main content
Discovering the causes of cancer and the means of prevention
 

Women exposed to DES in the womb face increased cancer risk

, by DCEG Staff

NIH researchers followed daughters of women given diethylstilbestrol during pregnancy and found increased fertility problems and cancer risks.

A large study of the daughters of women who had been given DES, the first synthetic form of estrogen, during pregnancy has found that exposure to the drug while in the womb (in utero) is associated with many reproductive problems and an increased risk of certain cancers and pre-cancerous conditions. The results of this analysis, conducted by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and collaborators across the country, were published Oct. 6, 2011, in the New England Journal of Medicine.

News Sources

NCI Cancer Bulletin (Archive): After DES: Tracking the harms of a prenatal drug exposure

News article in NCI’s bi-weekly newsletter the Cancer Bulletin (Archive)

NCI Cancer Bulletin: The DES story: Lessons learned

Video highlight in NCI’s bi-weekly newsletter the Cancer Bulletin

DCEG Linkage: The DES Follow-Up Study

Feature article in the DCEG Linkage Newsletter

< Older Post

NIH study finds two doses of HPV vaccine may be as protective as full course

Newer Post >

Women with BRCA1 and BRCA2 mutations survive ovarian cancer at higher rates than those without mutations